A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE PD01A Formulated With Adjuvant to Patients With Parkinson's Disease

Trial Profile

A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE PD01A Formulated With Adjuvant to Patients With Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Affitope PD01 (Primary) ; Aluminium oxide
  • Indications Parkinson's disease
  • Focus Adverse reactions; Biomarker; First in man
  • Sponsors AFFiRiS
  • Most Recent Events

    • 31 Jul 2014 Results published in an AFFiRiS media release.
    • 31 Jul 2014 Primary endpoint (Tolerability/Safety) has been met, according to an AFFiRiS media release.
    • 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top